Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. (Q38076053)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Adam B Davis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christoph C Zielinski

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

23 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23340862%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-013-2410-8

22 February 2020

exact match

0 references

cites work

The changing global patterns of female breast cancer incidence and mortality

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Anti-HER2 vaccines: new prospects for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Tumors as organs: complex tissues that interface with the entire organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Immune regulation of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Development of vaccines for high-risk ductal carcinoma in situ of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

DNA vaccination strategies for anti-tumour effective gene therapy protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Combined chemoimmunotherapy of solid tumours: improving vaccines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Vaccines for tumour prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Strategies for cancer vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Immunology and breast cancer: therapeutic cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Carcinoembryonic antigen-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Biology of HER2 and its importance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Recent advances in novel targeted therapies for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

DNA vaccines: developing new strategies against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Influenza virosomes as a vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Adjuvants for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Immunoglobulin A: A next generation of therapeutic antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2410-8